Experience in using Aterixen® in clinical practice. Results of the "SUPRA" observation program
- Authors: Kulagina I.T.1, Bagaeva M.I.2
-
Affiliations:
- Burdenko Main Military Clinical Hospital
- JSC Valenta Pharm Pharmaceutical Company
- Issue: Vol 25, No 9 (2023): Otorhinolaryngology and pulmonology
- Pages: 573-576
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/253571
- DOI: https://doi.org/10.26442/20751753.2023.9.202401
- ID: 253571
Cite item
Full Text
Abstract
Background. The new medical product Aterixen® (XC221GI) has appeared on the pharmaceutical market in 2022. It was revealed, at preclinical stage, that the main anti-inflammatory drug's effect was assured by its effect on production of anti-inflammatory cytokines IL-6, IL-8 and chemokines IP-10 (CXCL10), MIG (CXCL9). The results of double-blind randomized placebo-controlled studies have shown high efficacy of the drug in the management of patients with new coronavirus infection (COVID-19) of different severity.
Aim. To evaluate experience of Atherixen® practical use among physicians and general practitioners.
Materials and methods. The observational program included patients aged from 18 to 60 years with confirmed diagnosis of mild COVID-19. All patients have signed voluntary informed consent to participate in the study. The study consisted of 2 periods: screening period and drug administration period. All patients received Aterixen® (100 mg tablets), 1 tablet 2 times per day for 14 days within the standard therapy outlined in the Temporary methodological recommendations on prevention, diagnosis, and treatment of COVID-19. Efficacy was assessed by mean disease duration and physician and patient treatment satisfaction via five-point Likert scale.
Results. The average disease duration did not exceed 9.5 days. It indicates the ability of Aterixen® to prevent the transition of the disease to moderate and severe forms. The degree of physician and patient treatment satisfaction via five-point Likert scale in the vast majority of cases corresponded to the highest grades. Moreover, no adverse events were reported during the study and all patients had high tolerability.
Full Text
##article.viewOnOriginalSite##About the authors
Irina T. Kulagina
Burdenko Main Military Clinical Hospital
Email: madina.bagaeva@valentapharm.com
Cand. Sci. (Med.), Burdenko Main Military Clinical Hospital
Russian Federation, MoscowMadina I. Bagaeva
JSC Valenta Pharm Pharmaceutical Company
Author for correspondence.
Email: madina.bagaeva@valentapharm.com
ORCID iD: 0000-0002-4577-1832
Medical Advisor, JSC Valenta Pharm Pharmaceutical Company
Russian Federation, MoscowReferences
- Globenko AA, Kuzin GV, Rydlovskaya AV, et al. Curtailing virus-induced inflammation in respiratory infections: emerging strategies for therapeutic interventions. Front Pharmacol. 2023;14:1087850. doi: 10.3389/fphar.2023.1087850
- Стукова М.А., Рыдловская А.В., Проскурина О.В., и др. Фармакодинамическая активность нового соединения XC221GI в in vitro и in vivo моделях вирусного воспаления респираторного тракта. MIR J. 2022;9(1):56-70 [Stukova MA, Rydlovskaya AV, Proskurina OV, et al. In vitro and in vivo pharmacodynamic activity of the new compound XC221GI in models of the viral inflammation of the respiratory tract. MIR J. 2022;9(1):56-70 (in Russian)] doi: 10.18527/2500-2236-2022-9-1-56-70
- Временные методические рекомендации по профилактике, диагностике и лечению новой коронавирусной инфекции, версия 17 (14.12.2022 г.). М., 2022 [Guidelines "Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)", version 17. Moscow, 2022 (in Russian)].
- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7. doi: 10.1111/jth.14768
- Бицадзе В.О., Хизроева Д.Х., Гри Ж.-К, и др. Патогенетическое и прогностическое значение воспаления и нарушений в оси ADAMTS13/vWF у больных тяжелой формой COVID-19. Акушерство, гинекология и репродукция. 2022;16(3):228-43 [Bitsadze VO, Khizroeva JK, Gris J, et al. Pathogenetic and prognostic significance of inflammation and altered ADAMTS-13/ vWF axis in patients with severe COVID-19. Obstetrics, Gynecology and Reproduction. 2022;16(3):228-43 (in Russian)]. doi: 10.17749/2313-7347/ob.gyn.rep.2022.327
- Калюжин О.В., Баранова А., Багаева М.И. Стратегия управления вирус-индуцированным воспалением при COVID-19. Результаты многоцентрового адаптивного рандомизированного двойного слепого плацебо-контролируемого исследования у амбулаторных пациентов. Инфекционные болезни. 2023;21(1):26-34 [Kalyuzhin OV, Baranova A, Bagaeva MI. Management strategy for virus-induced inflammation in COVID-19. Results of a multicenter, adaptive, randomized, double-blind, placebo-controlled study in outpatients. Infectious Diseases. 2023;21(1):26-34 (in Russian)]. doi: 10.20953/1729-9225-2023-1-26-34
- Горелов А.В., Калюжин О.В., Багаева М.И. Новые возможности упреждающей противовоспалительной терапии пациентов со среднетяжелой и тяжелой формой COVID-19. Терапевтический архив. 2022;94(7):872-5 [Gorelov AV, Kalyuzhin OV, Bagaeva MI. New opportunities for preventive anti-inflammatory therapy in the management of patients with moderate and severe COVID-19. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(7):872-5 (in Russian)]. doi: 10.26442/00403660.2022.07.201729
- Колбин А.С., Белоусов Д.Ю., Зырянов С.К., и др. Исследования реальной клинической практики. М.: ОКИ: Буки Веди, 2020 [Kolbin AS, Belousov DIu, Zyrianov SK, et al. Issledovaniia real'noi klinicheskoi praktiki. Moscow: OKI, Buki Vedi, 2020 (in Russian)].
- Татарова Г.Г. Методология анализа данных в социологии (введение). Учебник для вузов. М.: NOTA BENE, 1999 [Tatarova GG. Metodologiia analiza dannykh v sotsiologii (vvedeniie). Uchebnik dlia vuzov. Moscow: NOTA BENE, 1999 (in Russian)].